More than 100 industry players and over 60 non-industry players currently claim to manufacture different types of cell therapies, either for in-house requirements or on contract basis
Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers .

Owing to various reasons, the demand for cell therapies isanticipated to increase over the coming years. Therefore, both therapydevelopers and contract service providers may need to strengthen theircapabilities and expand available capacity. In this context, automation isexpected to be a key enabler within the cell therapy manufacturing and contractservices industry

 

To order this 550+ page report, which features160+ figures and 250+ tables, please visit this link

 

The USD 11 billion (by 2030) financial opportunitywithin the cell therapy manufacturing market has been analyzed across thefollowing segments:

§  Typeof therapy

§  T-celltherapies (CAR-T therapies, TCR therapies, TIL therapies)

§  Dendriticcell therapies

§  Tumorcell therapies

§  NKcell therapies

§  Stemcell therapies

 

§ Source of cells

§ Autologous

§ Allogeneic

 

§  Scaleof operation

§ Clinical

§ Commercial

 

§  Purposeof manufacturing

§ Contract manufacturing

§ In-house manufacturing

 

§  Keygeographical regions

§  North America

§  Europe

§  Asia Pacific

§  Rest of the world

 

The Cell Therapy Manufacturing Market (3rdEdition), 2019 - 2030 report features the following companies, which weidentified to be key players in this domain:

§ BioNTech Innovative Manufacturing Services

§ Cell Therapies

§ Cell and Gene Therapy Catapult

§ Center for Cell and Gene Therapy, Baylor College ofMedicine

§ Centre for Cell Manufacturing Ireland, National Universityof Ireland

§ Clinical Cell and Vaccine Production Facility, Universityof Pennsylvania

§ Cognate BioServices

§ FUJIFILM

§ Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital

§ Hitachi Chemical

§ KBI Biopharma

§ Laboratory for Cell and Gene Medicine, Stanford University

§ Lonza

§ MaSTherCell

§ MEDINET

§ Molecular and Cellular Therapeutics, University ofMinnesota

§ Newcastle Cellular Therapies Facility, Newcastle University

§ Nikon CeLL innovation

§ Rayne Cell Therapy Suite, King’s College London

§ Roslin Cell Therapies

§ Scottish National Blood Transfusion Services CellularTherapy Facility, Scottish Centre for Regenerative Medicine

§ Sydney Cell and Gene Therapy

§ WuXi Advanced Therapies

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Market Overview

 

5. Regulatory Landscape

6. Roadmaps for Overcoming Existing Challenges

 

7. Automation Technologies for Cell Therapy Manufacturing

8. Profiles: Industry Players

9. Profiles: Non-Industry Players

10. Role of Non-Profit Organizations

11. Partnerships

12. Facility Expansions

13. Capacity Analysis

 

14. Demand Analysis

 

15. Cost Price Analysis

 

16. Make Versus Buy Decision Making Framework

 

17. Market Sizing and Opportunity Analysis

 

18. Key Insights

 

19. SWOT Analysis

 

20. Conclusion

 

21. Survey Analysis

 

22. Interview Transcripts

 

23. Appendix 1: Tabulated Data

 

24. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit Cell Therapy Manufacturing Market (3rdEdition), 2019 - 2030

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com